Mostrar Noticias:

BSXPrincipalesÚltima Hora

 Ver noticias de otros activos

Búsqueda de noticias relacionadas a la acción Boston Scientific (ordenadas por fecha):

Boston scientific anuncia datos positivos sobre la válvula aórtica Lotus? Noticias Médicas (Comunicado de prensa) Boston Scientific Corporation (NYSE: BSX) anuncia los resultados de factibilidad del estudio REPRISE I, en el que se evaluó la seguridad aguda de la válvula aótica Lotus? en los pacientes con valvulopatía aórtica. La válvula aórtica Lotus es el primer ...

Boston Scientific anuncia datos positivos sobre la válvula aórtica LotusE Finanzas.com Boston Scientific Corporation anuncia los resultados de factibilidad del estudio REPRISE I, en el que se evaluó la seguridad aguda de la válvula aótica Lotus(TM) en los pacientes con valvulopatía aórtica. La válvula aórtica Lotus es el primer ... COMUNICADO: Boston Scientific anuncia datos positivos sobre la válvula aórtica ...Cotizalia.com los 8 artículos informativos »

Boston Scientific anuncia el marcado ce y la presentación en el mercado ... Finanzas.com (14 de mayo de 2012): Boston Scientific Corporation anuncia el marcado CE y la presentación en el mercado europeo del stent vascular autoexpansible Innova(TM), que se ha diseñado para tratar las lesiones vasculares periféricas en las arterias ... y más »

COMUNICADO: El stent PROMUS Element? demuestra una seguridad y efectividad ... Europa Press Boston Scientific Corporation anuncia los resultados obtenidos tras dos años del estudio PLATINUM Small Vessel, que han demostrado una seguridad y efectividad excelentes con el stent liberador de everolimús PROMUS Element(TM), de 2,25 mm, fabricado en ... El stent PROMUS Element? demuestra una seguridad y efectividad excelentes en ...Asturi.as los 5 artículos informativos »

COMUNICADO: Boston Scientific presenta garantías de hasta 10 años para los dai ... elEconomista.es Boston Scientific Corporation ha anunciado que ampliará hasta 10 años, dependiendo del modelo, la garantía de los desfibriladores automáticos implantables (DAI) Energen(TM) y de los desfibriladores con terapia de resincronización cardíaca (CRT-D) ... y más »

Boston Scientific presenta garantías de hasta 10 años para los dai y CRTD ... Finanzas.com Boston Scientific Corporation ha anunciado que ampliará hasta 10 años, dependiendo del modelo, la garantía de los desfibriladores automáticos implantables (DAI) Energen(TM) y de los desfibriladores con terapia de resincronización cardíaca (CRT-D) ... y más »

COMUNICADO: Un estudio del dispositivo de primera clase WATCHMAN® muestra una ... Europa Press Boston Scientific Corporation ha anunciado los resultados del estudio ASA Plavix (ASAP), en el que se evaluó el dispositivo WATCHMAN(R) para el cierre de la orejuela auricular izquierda (OAI). Los datos mostraron una reducción del 75 % en el riesgo de ... Empresas.- El dispositivo 'Watchman' reduce un 75 por ciento el riesgo de ...elEconomista.es los 15 artículos informativos »

COMUNICADO: Los resultados al cabo de un año del estudio clínico EVOLVE ... Europa Press (Comunicado de prensa) Boston Scientific Corporation anuncia que SYNERGY(TM), el stent coronario liberador de everolimus, de cromo-platino, recubierto de un polímero bioabsorbible, demostró resultados de no inferioridad en el tratamiento de lesiones de novo en las arterias ... y más »

COMUNICADO: El S-ICD® System de Cameron Health cumple las conclusiones de ... Europa Press Los datos se presentaron en Heart Rhythm 2012, las 33rd Annual Scientific Sessions de la Heart Rhythm Society en Boston, MA por Martin C. Burke, DO, de la University of Chicago como parte de la sesión científica de última hora. y más »

El stent PROMUS Element H? °? ? ?? ? x? ð? X? È? 8? ?? ? ª ?ª « ?« ¬ `¬ ج P Ð ... Finanzas.com Esta declaración de advertencia es de aplicación a todas las afirmaciones de carácter prospectivo contenidas en el presente documento. [TAB] Contacto: Boston Scientific Ibérica Dina Hurtado García Coordinadora de Comunicación +34-629-12-94-31 ...

Boston Scientific Presents Data During Digestive Disease Week EndoNurse Boston Scientific Corporation this week presented seven abstracts and additional clinical data analyses at Digestive Disease Week, in San Diego. The analyses involve the SpyGlass® Direct Visualization System, WallFlex® Biliary RX Stent, Expect? 19 ...

Qué.es

La Clínica Universidad de Navarra implanta un estimulador en el nervio vago ... Qué.es En concreto, la intervención se enmarca dentro de un ensayo clínico multicéntrico europeo randomizado --aleatorio--, denominado 'NECTAR' y patrocinado y enteramente financiado por la multinacional 'Boston Scientific', que pretende probar la seguridad y ... y más »

RTT News

Boston Scientific Corp (NYSE:BSX) shares were trading at $5.99 while reporting ... The Mumbai Times The 17 analysts offering 12-month price forecasts for Boston Scientific Corp have a median target of 6.50, with a high estimate of 11.00 and a low estimate of 5.50. The median estimate represents a +8.51% increase from the last price of 5.99. Medtronic 4Q Profit Rose 28% On Fewer Charges4-traders Medtronic Posts Mixed Numbers - Analyst BlogNASDAQ Medtronic Posts Mixed NumbersInvestorIdeas.com (press release) Wall Street Journal -Zacks.com los 48 artículos informativos »

Un estimulador en el nervio vago alivia los síntomas de la insuficiencia cardiaca ABC.es El ensayo clínico está patrocinado y enteramente financiado por la multinacional Boston Scientific. Según indica la cardióloga Naiara Calvo, un estudio similar se ha efectuado con anterioridad en modelo animal, «en el que se ha comprobado que los ... y más »

Un electroestimulador en un nervio intenta combatir la insuficiencia cardiaca El País.com (España) Lo patrocina la multinacional Boston Scientific, y el implante que ha realizado la Clínica de la Universidad de Navarra es el cuarto del mundo. ?Se trata de una intervención sofisticada, pero de bajo riesgo, que se realiza bajo anestesia general, ...

Vaginal Mesh Lawsuits: An Overview InjuryBoard.com Plaintiffs allegedly suffer from injuries from vaginal mesh products made by American Medical Systems, Boston Scientific, Ethicon, and CR Bard. Women implanted with vaginal mesh for the treatment of conditions like pelvic organ prolapse (POP) and ... y más »

Mass High Tech

Boston Scientific Announces FDA Approval and U.S. Launch of EPIC? Vascular Stent Sacramento Bee By Boston Scientific Corporation NATICK, Mass., May 17, 2012 -- /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announces US Food and Drug Administration approval and market launch of the Epic? Vascular Self-Expanding Stent System. Boston Scientific Announces FDA Approval and US Launch of EPIC(TM) Vascular StentMarketWatch (press release) Boston Scientific wins approval for new leg stentCBS News Boston Scientific Announces FDA Approval And US Launch Of EPIC Vascular StentNASDAQ BioMedReports (subscription) los 35 artículos informativos »

Alan H. Robbins MD Joins Relevant Data Scientific Advisory Board; Formerly ... MarketWatch (press release) DANVERS, MA, May 23, 2012 (MARKETWIRE via COMTEX) -- Relevant Data Corp www.relevantdata.com welcomes Alan H. Robbins, MD formerly President and CEO of the New England Baptist Hospital to its Scientific Board of Advisors. With over 30 years experience ... y más »

COMUNICADO: Recomendada la aprobación del Sistema S-ICD® de Cameron Health ... ecodiario El 8 de marzo de 2012, Boston Scientific Corporation anunció que ejercitaría su opción para adquirir Cameron Health, Inc. El cierre de la transacción está sujeta a condiciones habituales, incluyendo una importante acreditación antimonopolio, ... y más »

Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive ... MarketWatch (press release) NATICK, Mass., May 18, 2012 /PRNewswire via COMTEX/ -- Boston Scientific Corporation (NYSE:BSX) announces that seven abstracts and additional clinical data analyses will be presented at Digestive Disease Week® (DDW), May 19 - 22 in San Diego. y más »

Boston Scientific Announces CE Mark and European Launch of Innova(TM) Self ... MarketWatch (press release) NATICK, Mass., May 14, 2012 /PRNewswire via COMTEX/ -- Boston Scientific Corporation (NYSE:BSX) announces CE Mark and European market launch of the Innova(TM) Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular ... Boston Scientific launches Innova self-expanding bare-metal stent system in ...pharmabiz.com Boston Scientific Announces CE Mark and European Launch of Innova? Self ...Sacramento Bee Boston Scientific And Philips Healthcare Announce Collaboration To Enhance ...Daily Markets MedCity News -Worcester Business Journal los 28 artículos informativos »

AngioDynamics Completes Acquisition of Navilyst Medical Private Equity Hub (press release) Avista Capital Partners acquired Navilyst Medical from Boston Scientific in 2008. Navilyst is a medical device company focused on areas including vascular access, interventional radiology and interventional cardiology. y más »

Local Employers on Board for Job Fair Patch.com Boston Scientific, Raytheon and others will be on hand to meet potential employees next month. More than two dozen companies will be on hand to meet job seekers next month when the city holds its first local job fair, part of Mayor Arthur Vigeant's ... ?Marlborough Works!" Job Fair Will Connect Area Businesses with Job Seekers on ...PR.com (press release) los 2 artículos informativos »

Boston Scientific Announces Positive Data From Lotus(TM) Transcatheter Aortic ... MarketWatch (press release) NATICK, Mass., May 15, 2012 /PRNewswire via COMTEX/ -- Boston Scientific Corporation (NYSE:BSX) announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus(TM) Aortic Valve System in patients with severe aortic ... Boston Scientific Announces Positive Data From Lotus? Transcatheter Aortic ...Sacramento Bee Boston Scientific Reports Data From Lotus Transcatheter Aortic Valve TrialRTT News Positive results from Boston Scientific's Lotus Aortic Valve System trialNews-Medical.net los 18 artículos informativos »

Clinical data from Boston Scientific endoscopy studies to be presented at DDW ... The Mumbai Times Boston Scientific Corp (NYSE:BSX) shares were trading at $5.96 while reporting down 2.30% from yesterdays close. The 17 analysts offering 12-month price forecasts for Boston Scientific Corp have a median target of 6.50, with a high estimate of 11.00 ... FDA Approval for BSX Epic StentZacks.com Boston Scientific gets FDA nod for vascular stentBoston Business Journal los 12 artículos informativos »

Boston Scientific Reports 2-yr Results From PLATINUM Small Vessel Study RTT News (RTTNews) - Boston Scientific Corp. (BSX: News ) announced two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element Everolimus-Eluting Platinum Chromium, or PtCr, ... PROMUS Element(TM) Stent Demonstrates Excellent Long-Term Safety and ...MarketWatch (press release) PROMUS Element? Stent Demonstrates Excellent Long-Term Safety and ...Sacramento Bee Boston Scientific: PROMUS Element Stent Demonstrates Excellent Long-Term ...Benzinga los 21 artículos informativos »

Boston Scientific gets FDA nod for medical device sales of new stent system MedReps Looking to repair its reputation in the vascular stent market and perhaps ensure future medical device jobs, Boston Scientific is launching its next generation of stenting products after winning approval by the Food and Drug Administration (FDA).

Midday Glance: Medical Devices companies CBS News Boston Scientific Corp. fell $.10 or 1.7 percent, to $5.84. Johnson & Johnson fell $.42 or .7 percent, to $63.10. Medtronic fell $.59 or 1.6 percent, to $36.37. St. Jude Medical Inc. fell $.45 or 1.2 percent, to $38.37. Stryker fell $.81 or 1.6 percent ... y más »

Medgadget.com

Boston Scientific's Ingenio Pacemaker Wins US FDA Approval BusinessWeek By Michelle Fay Cortez on May 07, 2012 Boston Scientific Corp. (BSX) (BSX)'s Ingenio and Advantio pacemakers won US approval to treat abnormally slow heartbeats, clearing the way for sales of devices that have been in development for a decade in the $4 ... Boston Scientific Announces FDA Approval and First U.S. Implant of New Devices ...MarketWatch (press release) Boston Scientific wins FDA approval for pacemakersBoston Herald Boston Scientific Reveals FDA Nod, Launch Of INGENIO, ADVANTIO & INVIVE CRT-PNASDAQ Pioneer Press los 36 artículos informativos »

Boston Scientific announces two-year results from PLATINUM Small Vessel study News-Medical.net Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element? Everolimus-Eluting Platinum Chromium (PtCr) Stent ... y más »

Boston Scientific Innova Has CE Mark Zacks.com Boston Scientific Corporation (BSX - Analyst Report) has strengthened its stent portfolio in Europe with the CE Mark approval and subsequent launch of Innova self expanding bare metal stent. The stent is designed to treat peripheral vascular lesions in ... Boston Scientific Introduces Stent System to EuropePatch.com Boston Scientific get European approval for new stentMinneapolis Star Tribune (blog) los 6 artículos informativos »

Boston Scientific Device Linked To Reduced Stroke Risk - Study Wall Street Journal (BSX), according to data from an trial released Friday. The multicenter company-funded study evaluated 150 patients implanted with Boston Scientific's device, called Watchman, and treated with dual antiplatelet therapy for six months post procedure. Boston Scientific anti-stroke device performs well in studyBoston Herald BOSTON SCIENTIFIC CORPORATION : Study of First-in-Class WATCHMAN® Device Shows ...4-traders Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke ...Sacramento Bee Benzinga los 21 artículos informativos »

Boston Scientific Announces Schedule For EuroPCR 2012 MarketWatch (press release) NATICK, Mass., May 10, 2012 /PRNewswire via COMTEX/ -- Boston Scientific Corporation (NYSE:BSX) announces its schedule of major events and sponsored clinical research at the annual EuroPCR Scientific Program, which takes place May 15 - 18 in Paris. y más »

Promus Element(tm) Stent Demonstrates Excellent Long-Term Safety and ... Stockhouse Boston Scientific Corporation (NYSE: BSX) announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element? Everolimus-Eluting Platinum Chromium (PtCr) Stent ... y más »

Medgadget.com

Boston Scientific plans global expansion Boston Herald By Frank Quaratiello Natick-based Boston Scientific, which holds more than 15000 patents and makes 13000 medical devices including heart pacemakers, is working hard to get its rhythm back. Fresh off positive first-quarter earnings and Food and Drug ... Boston Scientific's Ingenio Pacemaker Wins U.S. FDA ApprovalBloomberg FDA OKs Boston Scientific's New Line of PacemakersFox Business Boston Scientific gets FDA nod for Ingenio pacemakerBizjournals.com Medgadget.com -Minneapolis Star Tribune los 11 artículos informativos »

Boston Scientific Stays at Neutral Zacks.com We have reaffirmed our Neutral recommendation on Boston Scientific Corporation (BSX - Analyst Report) following its first quarter fiscal 2012 results. The challenges at Boston Scientific's core segments consisting of stents and defibrillators do not ... Zacks Gives Neutral Rating to Boston Scientific (BSX)Movie News Guide (blog) los 3 artículos informativos »

Boston Scientific Announces Schedule for Heart Rhythm Society Scientific Sessions MarketWatch (press release) NATICK, Mass., May 3, 2012 /PRNewswire via COMTEX/ -- Boston Scientific Corporation (NYSE:BSX) announces its schedule of major events and sponsored research at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, ... y más »

One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And ... MarketWatch (press release) NATICK, Mass., May 15, 2012 /PRNewswire via COMTEX/ -- Boston Scientific Corporation (NYSE:BSX) announces that the SYNERGY(TM) Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System demonstrated non-inferior results in ... EVOLVE Trial Clinical Results Confirm Data Of The Boston Scientific SYNERGY ...Science 2.0 Boston Scientific's Synergy bioabsorbable stent stands up to Promus ElementMass Device Citigroup Reiterates Neutral Rating, Raises PT for Boston ScientificBenzinga los 15 artículos informativos »

Mass High Tech

Boston Scientific Corporation (BSX) - Market Digest AVAFIN Shares of Boston Scientific Corporation closed at $5.96, down $0.14 (2.30%) in the last trading session. Today's volume of 28M shares is greater than the average volume of 14M shares. BSX is trading below the 50 day moving average and higher than the ... Breaking News: Three life sciences businesses among BBJ's top 10The Mumbai Times los 4 artículos informativos »

BOSTON SCIENTIFIC CORPORATION : Cameron Health Heart Device Seen As Safe ... 4-traders By Anjali Athavaley Of A heart device marketed by a closely held company that Boston Scientific Corp. (BSX) is acquiring was safe and effective, according to early results from an analysis of a registry released Thursday. Cameron Health Inc.'s device, ... Cameron Health's under-skin ICD safe, effectiveChicago Tribune Cameron Health's S-ICD® System Meets Primary Safety and Efficacy Endpoints in ...MarketWatch (press release) Study Shows Longer Arrhythmia Detection Window Reduces Shocks for Medtronic ...EON: Enhanced Online News (press release) NASDAQ los 45 artículos informativos »